Overweight and obese men have lower PSA values, even before they get prostate cancer

Men who are overweight or obese have lower concentrations of prostate-specific antigen (PSA) in their blood than their normal-weight counterparts, according to a new study led by Duke University Medical Center researchers.

The finding echoes earlier results on PSA concentrations found in obese and overweight men with prostate cancer and highlights the need to reconsider PSA threshold values for heavier patients, and to encourage those patients to get serious about losing weight.

“A study released last year from our group showed that obese and overweight men with prostate cancer had deceptively low PSA scores compared to normal-weight men with prostate cancer, but we now have extended our findings to show that this trend holds true in the general screening population,” said Marva Price, R.N., a family nurse practitioner and researcher in Duke’s School of Nursing, the Duke Comprehensive Cancer Center and the Duke Prostate Center.

“We found that mildly obese men’s PSA scores were fourteen percent lower than normal-weight men, and moderately and severely obese men had 29 percent lower PSA values,” Price said.

Doctors have proposed that overweight and obese men have lower PSA scores because their bodies have a greater volume of blood. Larger blood volumes dilute the amount of PSA in the bloodstream, making the concentration of PSA -- which is what is measured to screen for prostate cancer -- lower.

The latest results appear online in the Feb. 9, 2008 issue of the journal Urology. The study was funded by the United States Department of Defense.

PSA is considered the gold standard for detecting prostate cancer; it is a protein released into the blood by the prostate gland, and is elevated in the presence of cancer.

For this study, researchers looked at PSA scores among 535 men who took part in a free prostate cancer screening program. Seventy-three percent of the group was overweight or obese.

“The prevalence of obesity in the United States has doubled in the past 15 years,” Price said. “Our study demonstrates yet another health danger that obesity poses. One in three Americans is obese, and a man who is 5'11" and weighs 215 pounds is considered obese.

The best advice clinicians can give their patients is to adopt healthier lifestyles, said Stephen Freedland, M.D., a urologist at Duke and the study’s senior author. “We tell patients to exercise three or four times a week, eat a healthier diet, high in vegetables and fruits, and keep getting screened,” he said. However, to compensate for the lower PSA values, Freedland also recommends lowering the PSA threshold that is considered abnormal for obese men. “If we don’t do that, we may be missing cancers in obese men, which could lead to delayed diagnosis and poorer outcomes.”

Source: Duke University

Related stories:

PSA screening may be biased against obese men, leading to more aggressive cancers
Testing men for elevated levels of prostate-specific antigen (PSA) in the blood -- the gold standard screening test for prostate cancer -- may be biased against obese men, whose PSA levels tend to be deceptively low. And this bias may be creating more aggressive cancers in this population by delaying diagnosis, according to a new study led by investigators in the Duke Prostate Center and the Durham Veterans Affairs (VA) Medical Center.
Study suggests adjusting PSA scores for obese men or cancers may be missed
Doctors may be missing cancers in obese men because the telltale blood marker used to detect the disease can be falsely interpreted as low in this population, according to a new study led by Duke Prostate Center researchers.
New catheter-less technique may ease the pain and discomfort of prostate cancer recovery
To ease the pain of recovery following prostate cancer surgery, physician-scientists have developed an innovative and patient-friendly approach that eliminates the use of a penile urinary catheter. The new patentable technique, used in conjunction with robotic prostatectomy -- the surgical removal of the prostate -- eliminates the pain and discomfort associated with the standard catheter.
Study: When/if to start hormones for prostate cancer patients whose PSA rises after radiation
A new Fox Chase Cancer Center study suggests men with early stage prostate cancer treated with radiation therapy should begin hormone therapy immediately if their PSA level rises quickly and doubles within six months at any time after treatment. The study also supports foregoing hormones if the PSA doesn't rise as quickly. Both findings suggest a change in the practice of prescribing hormones is warranted.
Common painkillers lower levels of prostate cancer biomarker
Common painkillers like aspirin and ibuprofen appear to lower a man's PSA level, the blood biomarker widely used by physicians to help gauge whether a man is at risk of prostate cancer.
Health risk behaviors associated with lower prostate specific antigen awareness
According to a study conducted at Columbia University Mailman School of Public Health, health risk behaviors such as smoking and obesity are associated with lower awareness of the Prostate Specific Antigen (PSA), which could lead to a lower likelihood of undergoing actual prostate cancer screening. Although previous studies have explored predictors of PSA test awareness, this is the first research to focus on health risk behaviors, such as smoking, physical inactivity, obesity, and excessive alcohol consumption. The study findings were reported in the August issue of The Journal of Urology.
Hair on a man's head offers clues about prostate cancer
Some of the drugs given to many men during their fight against prostate cancer can actually spur some cancer cells to grow, researchers have found. The findings were published online this week in a pair of papers in the Proceedings of the National Academy of Sciences.
Prostatectomy improves outcome of some men with prostate cancer over watchful waiting
Men with early prostate cancer who undergo radical prostatectomy have a lower rate of death due to prostate cancer than men who are followed without treatment, known as watchful waiting, according to a randomized controlled trial published in the August 12 online issue of the Journal of the National Cancer Institute. The benefit from the surgery, with respect to prostate cancer death rates, remained constant beyond 10 years, but the overall death rates in the two groups were not statistically different. The applicability of the results to the current generation of prostate cancer patients is unclear, however, because few of the cancers treated in the trial were discovered by PSA (prostate-specific antigen) screening, a practice that is now widespread.

News discussion:

Medicine & Health news